Lien Gheyle

Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects

Benjamin Lang, Rod Ellis-Pegler, N. Czeloth, 2016, Expert opinion on investigational drugs.